Abstract
Idiopathic inflammatory bowel disease (IBD) includes a collection of disorders of the gastrointestinal tract of unknown aetiology, characterized by intestinal inflammation and a chronic relapsing course associated with local and systemic complications. Traditionally, IBD comprises two prototype entities, ulcerative colitis (UC) and Crohn’s disease (CD), and an intermediate variant of these diseases, indeterminate colitis, which shows overlapping features of the two major forms (Kirsner 1999).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bhatti M, Chapman P, Peters M, et al (1998) Visualizing E-selectin in the detection and evaluation of inflammatory bowel disease. Gut 43: 40–47
Caprilli R, Viscido A (1999) Evolving concepts on inflammatory bowel disease. Are we happy with the present nosology? Ital J Gastroenterol Hepatol 31: 893–987
Cho H (2001) The Nod2 gene in Crohn’s disease: implications for future research into the genetics and immunology of Crohn’s disease. Inflamm Bowel Dis 7: 271–275
Cominelli F (2000) Tumor necrosis factor modulation: from bench to bedside. Inflamm Bowel Dis 6: S21 - S22
D’Haens G (2000) Infliximab (Remicade): is the magic bullet for Crohn’s disease? Dig Liver Dis 32: 653–656
D’Haens G, Van Deventer S, Van Hogezand R, et al (1999) Endoscopic an histological healing with Infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 116: 1029–1034
Eigler A, Sinha B, Hartman G, Endres S (1997) Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18: 487–492
Farrell RJ, Peppercorn MA (2002) Ulcerative colitis. Lancet 359: 331–340
Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182–205
Goodnow C (2001) Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet 357: 2115–2121
Healy JI, Goodnow CC (1998) Positive versus negative signalling by lymphocyte antigen receptors. Annu Rev Immunol 16: 645–670
Hugot JP, Chamaillard M, Zouali H, et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411: 599–603
Karin M (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. The American society for biochemistry and molecular biology, Inc 270: 16483–16486
Kirsner JB (1999) Nonspecific inflammatory bowel disease (ulcerative colitis and Crohn’s disease) after 100 years–what next? Ital J Gastroenterol Hepatol 31: 651–658
Lugering A, Schmidt M, Lugering N, Paules HG, Domschke W, Kucharzik T (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 121: 1145–1157
Maccioni F, Viscido A, Broglia L, et al (2000) Evaluation of Crohn disease activity with magnetic resonance imaging. Abdom Imaging 25: 219–228
Mercurio F, Zhu H, Murray BW, Shevchenco A, et al (1997) Cytokine-activated IKB kinases essential for NF-KB activation. Science 278: 860–866
Ogura Y, Bonen DK, Inohara N, et al (200la) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411: 603–606
Ogura Y, Inohara N, Benito A, et al (2001b) Nod2, a Nod17APAF-1 family member that is restricted to monocytes and activates NF-KB. J Biol Chem 276: 4812–4818
Pallotta N, Baccini F, Corazziari E (2001) Small intestine contrast ultrasonography ( SICUS)in the diagnosis of small intestine lesions. Ultrasound Med Biol 27: 335–341
Papadakis KA, Targan SR (2000) Tumor necrosis factor: biology and therapeutic inhibitors.Gastroenterology 119: 1148–1157
Rampton DS (1999) Management of Crohn’s disease. BMJ 319: 1480–1485
Reimund JM, Wittersheim C, Dumont S, et al (1996) Increased production of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 39: 684–689
Sandborn WJ, Hanauer SB (1999) Antitumor necrosis factor therapy for inflammatory disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5: 119–133
Sands BE (1997) Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 3: 95–113
Shanahan F (2002) Crohn’s disease. Lancet 359: 62–69
Signore A, Chianelli M, Annovazzi A, et al (2000) 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn’s disease. J Nucl Med 41: 242–249
Signore A, Annovazzi A, Chianelli M, et al (2001) Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 28: 1555–1565
Tak PP, Firestein GS (2001) NF- KB: a key role in inflammatory diseases. J Clin Invest 107: 7–11
Van Deventer SJ (2001) Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. Gastroenterology 121: 1242–1246
Westermann B, Engelhardt B, Hoffmann JC (2001) Migration of T-cells in vivo: molecular mechanisms and clinical implications. Ann Intern Med 135: 279–95
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Viscido, A., Aratari, A., D’Ovidio, V., Guagnozzi, D., Annovazzi, A., Caprilli, R. (2003). The Gastroenterologist’s Update on Inflammatory Bowel Diseases. In: Signore, A., Liberatore, M., Scopinaro, F. (eds) Nuclear Medicine in the Management of Inflammatory and Infectious Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-05289-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-05289-1_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-07871-2
Online ISBN: 978-3-662-05289-1
eBook Packages: Springer Book Archive